Effect of estrone sulfate on postmenopausal bone loss

Area of Science:

• Reproductive Endocrinology
• Gerontology
• Pharmacology

Background:

• Estrogen replacement therapy (ERT) offers benefits for postmenopausal women, including bone loss prevention and reduced coronary artery disease risk.
• Bone loss accelerates in the immediate postmenopausal period, increasing fracture risk.
• Identifying the lowest effective ERT dose is crucial for balancing efficacy and safety.

Purpose of the Study:

• To determine the minimum effective daily dose of estrone sulfate combined with calcium for preventing spinal bone loss in postmenopausal women.
• To evaluate the dose-response relationship of estrone sulfate (0.3, 0.625, 1.25 mg) on bone mineral density.
• To assess the impact of estrone sulfate on lipid profiles and adverse events.

Main Methods:

• Multicenter, placebo-controlled study.
• Participants received daily estrone sulfate (0.3, 0.625, or 1.25 mg) plus 1000 mg elemental calcium, or placebo.
• Spinal bone mineral density measured by quantitative computed tomography at baseline and 12 months.

Main Results:

• Bone mineral density increased significantly with 0.625 mg (+1.9%) and 1.25 mg (+2.5%) daily estrone sulfate compared to baseline (P < .05).
• No significant difference in bone density increase was observed between the 0.625 mg and 1.25 mg doses.
• Estrone sulfate (0.625 and 1.25 mg) significantly altered lipid measurements at 6 and 12 months; adverse event rates were similar across groups.

Conclusions:

• Estrone sulfate 0.625 mg daily with 1000 mg calcium is the minimum effective dose to prevent spinal bone loss in postmenopausal women over 12 months.
• This dosage demonstrates a favorable balance of efficacy and safety.
• Further research may explore long-term effects and cardiovascular benefits.